← brief for 2026-08-26 · Slowing decline

Efficacy and safety of finerenone in adults with IgA nephropathy: a 12-month real-world study.

Key takeaways

Among 142 adults with IgA nephropathy, the drug finerenone lowered protein in the urine by about 35% and slowed kidney filtering rate decline over 12 months — but this small real-world study lacked a comparison group, so the exact benefit is uncertain.

Who did this work

Pei J (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Sun X (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Xu X (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Bai P (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Huang R (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Zhang J (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Chen X (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Yao L (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Shao L (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.) · Li Y (Department of Nephrology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.)

Source

Paper · Europe PMC, CKD · 2026-08-23
https://doi.org/10.1080/0886022x.2026.2681246